Q-linea (3F80) Stock Overview
Engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, European Union, the Middle East, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
3F80 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Q-linea AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.25 |
| 52 Week High | SEK 188.00 |
| 52 Week Low | SEK 0.10 |
| Beta | 0.96 |
| 1 Month Change | -14.45% |
| 3 Month Change | -54.27% |
| 1 Year Change | -98.73% |
| 3 Year Change | -99.92% |
| 5 Year Change | -99.98% |
| Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3F80 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -9.5% | 2.2% | 0.3% |
| 1Y | -98.7% | -1.1% | 12.3% |
Return vs Industry: 3F80 underperformed the German Medical Equipment industry which returned -1.1% over the past year.
Return vs Market: 3F80 underperformed the German Market which returned 12.3% over the past year.
Price Volatility
| 3F80 volatility | |
|---|---|
| 3F80 Average Weekly Movement | 8.9% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3F80's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3F80's weekly volatility has decreased from 11550% to 9% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 83 | Stuart Gander | qlinea.com |
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, European Union, the Middle East, and the United States. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture unit for incubating and detecting growth in blood bottles.
Q-linea AB (publ) Fundamentals Summary
| 3F80 fundamental statistics | |
|---|---|
| Market cap | €14.70m |
| Earnings (TTM) | -€17.24m |
| Revenue (TTM) | €982.18k |
Is 3F80 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3F80 income statement (TTM) | |
|---|---|
| Revenue | SEK 10.73m |
| Cost of Revenue | SEK 17.64m |
| Gross Profit | -SEK 6.91m |
| Other Expenses | SEK 181.46m |
| Earnings | -SEK 188.37m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Oct 29, 2025
| Earnings per share (EPS) | -29.27 |
| Gross Margin | -64.38% |
| Net Profit Margin | -1,755.24% |
| Debt/Equity Ratio | 46.3% |
How did 3F80 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/28 23:40 |
| End of Day Share Price | 2025/10/28 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Q-linea AB (publ) is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Ulrik Trattner | Carnegie Investment Bank AB |
| Mats Hyttinge | Redeye |